AU5076601A - Pulmonary delivery of ribavirin or levovirinTM for systemic and quasi-systemic treatment of disease - Google Patents
Pulmonary delivery of ribavirin or levovirinTM for systemic and quasi-systemic treatment of diseaseInfo
- Publication number
- AU5076601A AU5076601A AU50766/01A AU5076601A AU5076601A AU 5076601 A AU5076601 A AU 5076601A AU 50766/01 A AU50766/01 A AU 50766/01A AU 5076601 A AU5076601 A AU 5076601A AU 5076601 A AU5076601 A AU 5076601A
- Authority
- AU
- Australia
- Prior art keywords
- systemic
- levovirintm
- ribavirin
- quasi
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002685 pulmonary effect Effects 0.000 title 1
- 229960000329 ribavirin Drugs 0.000 title 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 title 1
- 230000009885 systemic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45966899A | 1999-12-13 | 1999-12-13 | |
| US09459668 | 1999-12-13 | ||
| PCT/US2000/042821 WO2001045642A2 (en) | 1999-12-13 | 2000-12-13 | Pulmonary delivery of ribavirin or levovirin™ for systemic and quasi-systemic treatment of disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU5076601A true AU5076601A (en) | 2001-07-03 |
Family
ID=23825713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU50766/01A Abandoned AU5076601A (en) | 1999-12-13 | 2000-12-13 | Pulmonary delivery of ribavirin or levovirinTM for systemic and quasi-systemic treatment of disease |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU5076601A (en) |
| WO (1) | WO2001045642A2 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050182252A1 (en) | 2004-02-13 | 2005-08-18 | Reddy K. R. | Novel 2'-C-methyl nucleoside derivatives |
| WO2011150441A1 (en) * | 2010-06-03 | 2011-12-08 | Wholesome Biopharm Pty Ltd | Medical aerosol formulation comprising ribavirin |
| EP3105238A4 (en) | 2014-02-13 | 2017-11-08 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and their uses |
| JP2017520545A (en) | 2014-07-02 | 2017-07-27 | リガンド・ファーマシューティカルズ・インコーポレイテッド | Prodrug compounds and their use |
| AU2019207625A1 (en) | 2018-01-09 | 2020-07-30 | Ligand Pharmaceuticals, Inc. | Acetal compounds and therapeutic uses thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4211771A (en) * | 1971-06-01 | 1980-07-08 | Robins Ronald K | Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide |
-
2000
- 2000-12-13 AU AU50766/01A patent/AU5076601A/en not_active Abandoned
- 2000-12-13 WO PCT/US2000/042821 patent/WO2001045642A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001045642A3 (en) | 2001-12-13 |
| WO2001045642A2 (en) | 2001-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001275177A1 (en) | Cardiac disease treatment and device | |
| AU2001253565A1 (en) | Cardiac disease treatment and device | |
| AU2001281369A1 (en) | Cardiac disease treatment and device | |
| AU2002252152A1 (en) | Tissue electroperforation for enhanced drug delivery and sampling | |
| AU5241199A (en) | Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin | |
| AU2002233643A1 (en) | Methods of treating diseases in association with decrease in the expression of AOP-1 gene or AOP-1 and remedies for the diseases | |
| AU1063201A (en) | Use of tgf beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa | |
| AU3356500A (en) | Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease | |
| AU7907300A (en) | Novel combination of loteprednol and antihistamines | |
| AU715620C (en) | Therapeutic methods and uses | |
| AU1164601A (en) | Therapeutic use and formulation | |
| AU2300001A (en) | Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease | |
| AU6083899A (en) | Combination of c1-inh and lung surfactant for the treatment of respiratory disorders | |
| AU5240700A (en) | Naphthoquinone derivatives and their use in the treatment and control of tuberculosis | |
| AU5262200A (en) | Arrangement in ventilatory treatment of the lungs | |
| AUPQ344799A0 (en) | Treatment of respiratory diseases and infections | |
| AU3593599A (en) | Drugs for reducing vaginal acidity and treatment of vaginitis, and the use thereof | |
| AU5076601A (en) | Pulmonary delivery of ribavirin or levovirinTM for systemic and quasi-systemic treatment of disease | |
| AU2002224471A1 (en) | In vivo stimulation of angiogenic activity | |
| AU4228000A (en) | Methods and compositions for the treatment and prevention of lung disease | |
| AU2002215187A1 (en) | S-adenosylmethionine and derivatives thereof for the treatment and prevention ofalzheimer's disease | |
| AU4053700A (en) | Enhanced tissue and subcellular delivery of vitamin e compounds | |
| AU4225500A (en) | Methods and compositions for the treatment and prevention of lung disease | |
| AU2001267177A1 (en) | Diagnosis and treatment of herpes infections | |
| AU1157500A (en) | Medicaments based on combinations of lacidipine and telmisartan or of physiological derivatives thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |